With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products... Show more
Novo Nordisk is one of the world's foremost metabolic-disease specialists, anchored by its blockbuster GLP-1 franchise spanning Ozempic and Rybelsus for type 2 diabetes and Wegovy for obesity. This chronic-care exposure gives the company a recurring revenue base, but its future outlook is increasingly defined by how well it defends and extends that franchise amid a fast-crowding competitive field.
The strategic pivot now centers on broadening the Wegovy platform. Improved manufacturing capacity underpins plans to launch the Wegovy pill in at least 20 countries by the end of 2027, a move management says would cover roughly two-thirds of the obesity market it currently serves. Orally delivered GLP-1 therapies could widen patient access and reduce the friction of injectables, but the pill's U.S. momentum is already a point of analyst debate, with JPMorgan flagging slowing domestic prescriptions even as international uptake accelerates.
Competitively, Eli Lilly has emerged as a formidable rival, with its next-generation candidates retatrutide and eloralintide, alongside oral and high-dose offerings, challenging Novo's efficacy lead. Roche, Pfizer, and AstraZeneca are also advancing competing assets. In response, Novo's pipeline — including CagriSema and the amylin-based candidate Zenagamtide (amycretin) — is central to whether it can sustain a differentiated position beyond semaglutide's patent life.
Several near- to medium-term events could materially shift investor sentiment:
The broader environment cuts both ways. U.S. pricing policy, including IRA-negotiated drug prices, continues to compress realized prices on key products, while management's guidance for "broadly stable" margins through 2030 reflects elevated research and development (R&D) investment and competitive discounting. European reimbursement questions — such as whether German public insurers should cover obesity medicines — could either unlock large addressable demand or constrain it, depending on policy outcomes.
Interest-rate dynamics also matter. Novo's valuation has de-rated sharply from a price-to-earnings (P/E) multiple above 40 in 2021 to roughly 10-11 times forward earnings, a reset that makes it more sensitive to long-duration growth expectations and discount-rate shifts. A durable dividend yield near 4% provides some support, but the stock's trajectory is likely to hinge more on pipeline execution and pricing stability than on macro tailwinds alone.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders assess whether a stock, ETF (exchange-traded fund), or other asset may trend bullish, bearish, or sideways over the next week or month. It helps users identify developing trends, evaluate potential breakouts or reversals, and explore predictions across a broad universe of tradable instruments. The platform includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. For investors tracking evolving setups in names like NVO, the Trend Prediction Engine can serve as a useful complement to fundamental analysis.
Consensus expectations point to a challenging 2026, with several analysts modeling a year-over-year decline in sales and earnings per share (EPS) as pricing pressure and competition bite. The medium-term outlook depends on three themes.
First, franchise diversification: Novo's ability to convert the Wegovy pill's early success into durable international volume, and to secure CagriSema and Zenagamtide milestones, will determine whether growth re-accelerates after 2027. Citi, for example, raised its peak-sales estimate for the Wegovy pill to $13 billion from $10 billion, underscoring the opportunity's scale.
Second, margin and cost structure: With management signaling stable margins through 2030 amid heavy R&D spending, the path to operating leverage may be more gradual than in the prior growth cycle. Higher capital expenditure and R&D intensity could keep free-cash-flow conversion constrained in the near term.
Third, the 2032 patent cliff: Semaglutide's U.S. exclusivity expiry looms as the defining long-term risk. Whether the next-generation pipeline can offset generic erosion will be the central question shaping how analysts and markets value the franchise beyond this decade.
These considerations frame why the analyst community has moved toward a Hold consensus, with an average one-year price target near $45 per the S&P Global consensus, reflecting measured optimism balanced against near-term earnings uncertainty.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, NVO has been loosely correlated with TECH. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if NVO jumps, then TECH could also see price increases.
| Ticker / NAME | Correlation To NVO | 1D Price Change % | ||
|---|---|---|---|---|
| NVO | 100% | -0.07% | ||
| TECH - NVO | 36% Loosely correlated | -0.01% | ||
| GMAB - NVO | 35% Loosely correlated | +0.39% | ||
| NVS - NVO | 30% Poorly correlated | -0.19% | ||
| AXON - NVO | 29% Poorly correlated | -2.85% | ||
| IMTX - NVO | 29% Poorly correlated | -3.44% | ||
More | ||||
| Ticker / NAME | Correlation To NVO | 1D Price Change % |
|---|---|---|
| NVO | 100% | -0.07% |
| NVO (1 stocks) | 61% Loosely correlated | -0.07% |
| Pharmaceuticals: Major (21 stocks) | 22% Poorly correlated | -2.15% |
| Pharmaceuticals (151 stocks) | 3% Poorly correlated | -2.18% |
a developer of pharmaceutical products
Industry PharmaceuticalsMajor
The 10-day moving average for NVO crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on NVO as a result. In 55 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
NVO moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVO advanced for three days, in 203 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
The Aroon Indicator entered an Uptrend today. In 161 of 255 cases where NVO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
The 10-day RSI Indicator for NVO moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 24 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 69%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 72 cases where NVO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
NVO broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron SMR rating for this company is 19 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating fairly steady price growth. NVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.805) is normal, around the industry mean (-1.421). P/E Ratio (1.534) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (4.416) is also within normal values, averaging (5.738). Dividend Yield (0.046) settles around the average of (0.038) among similar stocks. P/S Ratio (3.627) is also within normal values, averaging (4.033).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.